Sleep Disorders

Kristine Yaffe, MD, distinguished professor at UCSF and SEQUINS Hall of Fame honoree, discusses dementia prevention, modifiable risk factors, and ongoing disparities in brain health and cognitive aging.

As a 2026 SEQUINS Hall of Fame honoree, James Galvin, MD, MPH, reflected on advancing equitable dementia care, culturally relevant cognitive assessment, and improving brain health outcomes across diverse communities.

Catch up on any of the neurology headlines you may have missed from last week, compiled into 1 place by the NeurologyLive® team.

As a 2026 SEQUINS Hall of Fame honoree, George Howard, DrPH, commented on decades of stroke disparities research, the impact of the REGARDS study, and why future efforts must focus more directly on upstream risk factors.

As a 2026 SEQUINS Hall of Fame honoree, Edwin Trevathan, MD, MPH, reflects on global pediatric neurology, community-based care delivery, and the ongoing effort to reduce neurologic health inequities worldwide.

Catch up on any of the neurology headlines you may have missed in April 2026, compiled into 1 place by the NeurologyLive® team.

A recent study suggested that probiotic regimens and biomarker-guided strategies may be a promising signal for reducing excessive daytime sleepiness in patients with PD and CKD.

A phase 1b/2 trial presented at AAN 2026 showed HS-10506, a selective OX2R antagonist, significantly improved sleep latency and overall sleep outcomes in adults with insomnia.

Data from the phase 2 Vibrance-1 trial showed that alixorexton was associated with improvements in patient-reported outcomes in adults with narcolepsy type 1 over up to 12 to 13 weeks of follow-up.

An exploratory analysis of a phase 3 trial showed that solriamfetol improved daytime wakefulness without producing consistent or clinically meaningful changes in nocturnal sleep quality measures.

A recent population-based data analysis of Korean adults reported those with anxiety and certain sleep disturbances experienced longer durations of morning grogginess, known as sleep inertia.

A meta-analysis of randomized trials confirmed modafinil improves both objective and subjective measures of daytime sleepiness in narcolepsy.

Stay informed on the latest therapeutic advancements with this clinical recap from the NeurologyLive® team, featuring a centralized look at 7 FDA-approved treatments from the first quarter of 2026.

Alkermes has initiated the phase 3 Brilliance program for alixorexton in narcolepsy, building on prior phase 1 and 2 data showing significant improvements in wakefulness and daytime sleepiness.

Catch up on any of the neurology headlines you may have missed in March 2026, compiled into 1 place by the NeurologyLive® team.

A cross-sectional study suggests excessive daytime sleepiness may represent an independent, nonmotor feature of idiopathic normal pressure hydrocephalus, separate from apnea or disease severity.

A new obstructive sleep apnea study suggested that fatigue and objective daytime sleepiness are uncorrelated, challenging the use of the Epworth Sleepiness Scale as a measure of sleepiness.

In a preclinical study, subthalamic nucleus (STN) low-beta power negatively correlated with wake quantity, whereas STN and motor cortex high-beta power demonstrated a positive correlation with wakefulness.

Sleep medicine specialist Karin Johnson, MD, FAAN, FAASM, shared the main takeaways from a recently published guideline on evaluating and managing obstructive sleep apnea in hospitalized adults.

From FDA regulatory milestones for investigational agents to emerging clinical data across sleep disorders, this roundup highlights notable developments shaping the evolving landscape of orexin-targeted therapies.

New findings from a phase 3 trial conducted in China showed that solriamfetol boosted wakefulness and reduced daytime sleepiness in patients with obstructive sleep apnea, with manageable adverse effects.

A post hoc analysis of the AMPA observational study found that adjunctive perampanel did not worsen daytime sleepiness over 12 months in patients with focal epilepsy while maintaining substantial seizure reduction.

Catch up on any of the neurology headlines you may have missed in February 2026, compiled into 1 place by the NeurologyLive® team.

A cross-sectional analysis of nearly 28,000 middle-aged adults found that excessive daytime sleepiness is strongly associated with both sleep characteristics and modifiable psychological factors, highlighting the need for integrated prevention strategies.

A new study showed that higher baseline Epworth Sleepiness Scale scores were associated with greater early continuous positive airway pressure adherence in patients with obstructive sleep apnea.